• What’s the difference between a reference biologic drug and a biosimilar?
• Biosimilars: What’s Health Canada saying?
• What is the clinical evidence to date?
• How do doctors go about transitioning their patients from a reference biologic drug to a biosimilar?
We will also hear from two patients who have successfully transitioned from a reference biologic drug to a biosimilar.
Q&A period will follow – so come with your questions!
You must register to view the webinar.
Jeffrey McCurdy MD PhD FRCPC – Bio
Dr. Jeffrey McCurdy is an Assistant Professor of Medicine at the in the University of Ottawa, clinical investigator at the Ottawa Hospital Research Institute, and a member of the Inflammatory Bowel Disease (IBD) Center of excellence at The Ottawa Hospital.
He received his PhD in Immunology from Dalhousie University (2004), and his MD from the University of Ottawa (2007). He completed his training in Internal Medicine (2010), and Gastroenterology (2012) at Dalhousie University, and an advanced fellowship in IBD (2013) at Mayo Clinic, Rochester.
He is the co-chair of IBD Updates, a fully accredited program by the Canadian Association of Gastroenterology designed to review cutting edge research in IBD from each of the major international congresses for IBD, and a co-chair of the Canadian Gastroenterology Residents-in-Training (GRIT) Course. He is also the Chair of the Ottawa Hospital Multidisciplinary IBD rounds.
His research interests focus on understanding the role of infectious organisms in IBD exacerbations, identifying predictors of disease related outcomes in IBD, and strategies to improve the quality of care for IBD.